ImmuPharma plc (LON:IMM – Get Free Report)’s share price shot up 3.4% during mid-day trading on Monday . The stock traded as high as GBX 6.60 and last traded at GBX 6.60. 533,936 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 7,800,227 shares. The stock had previously closed at GBX 6.38.
ImmuPharma Stock Performance
The business’s 50 day moving average price is GBX 9.87 and its 200-day moving average price is GBX 6.11. The company has a market cap of £31.44 million, a price-to-earnings ratio of -7.03 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Stock Market Sectors: What Are They and How Many Are There?
- Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers
- Trading Halts Explained
- 10X Gains? These 3 Robotics Stocks Could Explode by 2035
- Quiet Period Expirations Explained
- Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
